SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Despite strong earnings, Broadcom's stock is trending due to a sharp pullback, sparking debates about market manipulation and AI sector overvaluation. Community members are actively discussing potential support levels and whether the dip represents a buying opportunity or a sign of further decline. Analyst price target updates add to the uncertainty, with some traders anticipating a rebound while others brace for continued volatility.

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending due to discussions around its low float and potential for a short squeeze, with community members comparing it to other high-flying stocks. Traders are actively watching key resistance levels and speculating on possible price targets, while also weighing concerns about the company's valuation and potential for a pullback. The stock's association with the robotics sector and its connection to AMC through its name are also contributing to the ongoing conversation.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco ($COST) is trending due to a recent analyst downgrade from Roth Capital, sparking debate about its valuation and growth prospects, especially compared to competitors like Walmart. The community is discussing whether this presents a buying opportunity or signals deeper concerns about membership growth and market saturation. Some investors are also closely watching for any news regarding a potential stock split or special dividend announcement.

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chun Sing Chan on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

CLIK is trending due to its nano float and Hong Kong connection, with traders anticipating a potential run similar to other low-float stocks. Community members cite recent acquisitions and revenue growth as catalysts, while also highlighting its low market capitalization. The stock's high borrow rate and potential for a short squeeze are also fueling interest.

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is founded by Paul A. Hopper in 2021 headquartered Carlton, Australia.

Radiopharm Theranostics Ltd - ADR

RADX is trending due to community excitement around its potential for a short squeeze, with many noting bullish technical formations and anticipating a breakout. The stock is also gaining attention due to positive interim data from its RAD 101 clinical trial, leading to speculation about future sales and potential buyout offers. Community members are actively discussing target prices and the possibility of the stock reaching significantly higher levels.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid speculation that the cannabis industry could be on the verge of significant reform, with community members closely watching for potential executive action. The central talking point revolves around the possibility of reclassification, with many expressing mixed sentiment due to the long history of the stock. Despite the hype, some traders are wary, pointing to past disappointments.

Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.

Artiva Biotherapeutics Inc

ARTV is trending as traders discuss a recent FDA Fast Track designation for its AlloNK therapy in refractory rheumatoid arthritis, with Wedbush setting a price target. Community members highlight the potential for a significant squeeze, referencing low float and high borrow rates. Some caution around potential offerings and the stock's volatile price action.

ARB IOT Group Ltd. is a holding company that engages in the provision of solutions for the integration of IoT systems and devices. It operates through the Internet of Things and Investment Holding and Others segments. The company was founded on March 1, 2022 and is headquartered in Singapore.

ARB IOT Group Ltd

ARBB is trending due to community hype around a potential short squeeze, fueled by its low float and comparisons to previous runners. Discussions highlight updated analyst target prices and the stock's volatile price action, with some traders anticipating a significant breakout. Community members are closely monitoring key price levels as potential triggers for further upward momentum.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is trending as investors assess the implications of its AI strategy and recent partnerships, with community discussions focusing on whether the company can maintain its growth trajectory amidst rising competition. Recent reports of a potential acquisition of cybersecurity firm Armis for $7B has sparked debate about valuation and strategic fit, contributing to market volatility. Despite long-term bullish sentiment from analysts, the stock's YTD performance has some questioning its current valuation and potential for short-term recovery.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending downwards, sparking debates about averaging down and the health of the data center trade. Community members are attributing the price drop to institutional repositioning or short pressure, while others remain confident in the company's fundamentals and future contracted revenue, viewing it as a buying opportunity amidst market volatility. Some traders are expressing frustration and hoping for news regarding a hyperscaler tenant to turn things around.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award

Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award...

Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston

Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston PR Newswire NEW YORK, Oct. 16, 2025 NEW YORK, Oct. 16, 2025...

Retail chatter around Klotho Neurosciences picked up late Thursday after the company said that the FDA had granted Orphan Drug Designation to its ALS gene therapy candidate, KLTO-202.The designation is reserved for treatments targeting rare diseases and comes with several incentives to support development.&nbsp;These include seven years of market exclusivity, tax credits for clinical trials, and a waiver of the generic drug user fee amendments (GDUFA) user fee, independent of existing intellectual property rights.At the close on Thursday, shares of&nbsp;<a href="https://stocktwits.com/symbol/KLTO">Klotho Neurosciences</a> rose 6.6% to $1.46, before slipping 6.9% to $1.36 in after-hours trading.Last month, the company reported efforts to move forward with manufacturing and process development in preparation for clinical trials of KLTO-202.&nbsp;Klotho holds rights to a unique RNA splice variant of the human alpha‑Klotho gene, licensed from the Autonomous University of Barcelona.&nbsp;This variant produces the secreted form of Klotho protein (s‑KL), known for its neuroprotective properties in the brain and spinal cord.Animal studies conducted in mouse and non-human primate models of accelerated aging, Alzheimer's disease, and ALS have demonstrated that boosting s‑KL through gene therapy yields therapeutic benefits across all tested models, according to peer-reviewed journals.&nbsp;These findings support KLTO-202’s progression into clinical development.The company expects that process development and manufacturing will take about eight months, followed by four to six months of FDA meetings, mandated animal safety studies, an investigational new drug (IND) filing, and site preparations.&nbsp;A single-dose Phase I/II trial in ALS patients is planned for the third quarter of next year.&nbsp;In a statement, CEO Joseph Sinkule said that the therapy’s goal is to deliver therapeutic s‑KL concentrations to blood, brain, and muscle tissue.KLTO-202, which uses a muscle-specific desmin promoter to drive s‑KL expression at the neuromuscular junction, remains unapproved for human use.On Stocktwits, retail sentiment for Kloto was ‘bullish’ amid ‘high’ message volume.Kloto’s stock has more than doubled in value so far in 2025.See also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/china-s-byd-chery-accused-of-subsidy-misuse-as-ev-audit-flags-121-m-in-claims/ch8c5XCR5mQ">China’s BYD, Chery Accused Of Subsidy Misuse As EV Audit Flags $121M In Claims</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Kloto Neurosciences (KLTO) said that the FDA had granted Orphan Drug Designation to its ALS gene therapy candidate, KLTO-202. (Photo credit: Getty Images)

Klotho Neurosciences Stock Jumps As FDA Grants Orphan Drug Tag To ALS Gene Therapy

The FDA’s Orphan Drug Designation offers incentives like seven years of U.S. market exclusivity, tax credits for clinical trials, and a waiver of the user fee for its ALS gene therapy.

Equity

Klotho Neurosciences (KLTO) shares exploded over 780% on Monday, their biggest single-day gain on record, after the company announced breakthrough preclinical results tied to its anti-aging gene therapy.The Omaha, Nebraska-based biotech said boosting levels of a naturally occurring protein called s-KL (secreted Klotho) extended lifespan in mice by 20% and reduced signs of aging across multiple organ systems.&nbsp;The gene therapy, delivered via the AAV9 vector, showed positive effects in both standard and accelerated aging models."The results disclosed in the paper show the potential of elevating s-KL protein expression, resulting in the reduction of age-associated degeneration in multiple organs, increasing both life and health span," said CEO Joseph Sinkule.&nbsp;Klotho owns exclusive global rights to the patented therapy, based on pioneering work from researchers at Universitat Autònoma de Barcelona. The company said its patent coverage spans the U.S., Europe, and China.Earlier studies had shown that mice with increased Klotho expression could live up to 40% longer.Retail Traders Go WildThe update triggered a retail frenzy on Stocktwits as 24-hour message volume about KLTO jumped by 250,400% — the biggest surge in the healthcare sector — while the follower count spiked by over 134%.Sentiment score peaked at ‘extremely bullish’ levels (100/100) by the end of Monday.<figure class="image"><img style="aspect-ratio:1318/914;" src="https://news.stocktwits-cdn.com/KLTO_sentiment_and_message_volume_as_of_Jun_9_png_d3adf0d02d.webp" alt="KLTO sentiment and message volume as of Jun 9.png" width="1318" height="914"><figcaption>KLTO sentiment and message volume as of Jun 9. | source: Stocktwits</figcaption></figure>One user predicted the stock would surge nearly fivefold to $5.<stembedurl>https://stocktwits.com/Kcricket33/message/617354438</stembedurl>"Pretty wild news, obviously digested well today… will watch for continuation tomorrow using the pivot of today's highs in confluence with trend support as entry criteria. Range to $2.8, $3+," said another.<stembedurl>https://stocktwits.com/KevMomentum/message/617353716</stembedurl>Klotho is targeting neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS, leveraging s-KL in both DNA/RNA therapies and genomics-based diagnostics.<a href="https://stocktwits.com/symbol/KLTO">KLTO stock</a> is now up over 271% YTD, returning to levels last seen in July 2024.&nbsp;However, short interest has also climbed, rising from 1.1% in January to 7.1% last week, per Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Klotho Neurosciences Stock Skyrockets On Anti-Aging Gene Therapy Breakthrough: Retail Traders Over The Moon

The gene therapy, delivered via the AAV9 vector, showed positive effects in both standard and accelerated aging models.

Klotho Neurosciences, Inc. engages in the provision of new therapies to treat neurodegenerative diseases. It offers cell and gene therapy. The company was founded by Joseph Sinkule on August 2, 2004 and is headquartered in Omaha, NE.

Current Price	$0.3833
Prev Close	$0.4004
Open	$0.4124
Dividend Yield	0.00%
50-Day Moving Average	$0.5111
Beta	1.12
Avg. Volume	734,399.11
PE Ratio	-1.23

52-Week High	$3.91
52-Week Low	$0.1135
Market Capitalization	$29.04M
EPS (Annual)	-$0.3195
Price to Book	2.84
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

KLTO
Klotho Neurosciences Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest KLTO News

KLTOKlotho Neurosciences Inc.